Journal profile · Medicine-Hematology
Blood Advances
ISSN 2473-9529 · eISSN 2473-9537 · American Society of Hematology · UNITED STATES
Blood Advances: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 7.6; fully open access; APC about USD 4,000; median 107 days to acceptance (148 articles, last 24 months); 791 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Blood Advances is published by American Society of Hematology and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment and CAR-T cell therapy research, together about 27.1% of its articles. Its main subfields are Hematology and Genetics. (generated from OpenAlex topic counts and CAS ranking data)
Blood Advances, a Journal of the American Society of Hematology, published online and open access, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology and related sciences. Blood Advances will complement Blood by publishing content not currently covered including case reports, point-counterpoint discussions, and by providing forums to readily comment on published material. The electronic format of Blood Advances provides an opportunity to explore novel approaches for presentation of original content including the use of enhanced graphics, video and online discussion. Additionally, it is hoped that Blood Advances will serve as a hub for dissemination of educational and service needs by providing scholarly content and expert consultation requested by interested parties.Acceptance of manuscripts is based on the originality or importance of the observations and investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well organized, and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.Blood Advances has recently added a new scientific category for Health Services and Outcomes submissions. The journal is very interested in submissions as reflected in the definition here.Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Health Services and Outcomes (new); Hematopoiesis and Stem Cells; Immunobiology; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.Authors are invited to contact the Editor-in-Chief prior to submission if they are uncertain whether their work falls within the general scope of the journal. For presubmission inquiries regarding the journal scope, please contact the Blood Advances Editorial Department and include an abstract or detailed summary for consideration.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Hematology
Editor-in-chief Catherine M. BollardPublisher website
Editorial board by country: none in mainland China; most named United States 64, Australia 7, United Kingdom 6, Germany 2, Canada 2 (87 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Acute Myeloid Leukemia ResearchMedicine10.1%
- Lymphoma Diagnosis and TreatmentMedicine9.5%
- CAR-T cell therapy researchMedicine7.5%
- Hematopoietic Stem Cell TransplantationMedicine6.7%
- Chronic Lymphocytic Leukemia ResearchMedicine6.5%
- Platelet Disorders and TreatmentsMedicine5.1%
- Acute Lymphoblastic Leukemia researchMedicine5%
- Hemoglobinopathies and Related DisordersMedicine4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.6LetPub ·
- Impact factor (publisher)
- 7.7Publisher website ·
- CiteScore 2026-06
- 11.8LetPub ·
- CiteScore (publisher)
- 11.8Publisher website ·
- SJR 2026-06
- 3.11LetPub ·
- SNIP 2026-06
- 1.75LetPub ·
- h-index
- 133OpenAlex ·
- i10-index
- 3,612OpenAlex ·
- 2-year mean citedness
- 5.72OpenAlex ·
- Self-citation rate
- 3.9%LetPub ·
- Share of gold OA articles
- 99.75%LetPub ·
Volume
- Articles per year
- 494LetPub ·
Articles by year OpenAlex count · 6,287 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 678 | 678 | 491 |
| 2025 | 791 | 791 | 3,884 |
| 2024 | 737 | 737 | 8,249 |
| 2023 | 664 | 664 | 11,758 |
| 2022 | 762 | 762 | 17,626 |
| 2021 | 758 | 758 | 28,528 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
107 daysMedian, submission to acceptance · P25–P75 70 days – 151 days
- Acceptance to online
- median 27 days (54 articles)
- Submission to online
- median 153 days
- Sample
- 148 articles with submission and acceptance dates (1,794 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,000 | Yes | CC BY-NC-ND | |
| OpenAlex | USD 3,800 / EUR 3,550 / GBP 3,040 / JPY 471,310 | — | — | |
| Publisher website | USD 4,000 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 4,000 (excluding taxes). Review this journal’s open access policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- American Society of Hematology
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2473-9529
- Electronic ISSN
- 2473-9537
- Official links
FAQ
Frequently asked questions about Blood Advances
What CAS zone is Blood Advances in?
In the 2025 upgraded edition of the CAS Journal Ranking, Blood Advances is in Zone 1 of Medicine, and in Zone 2 of the minor category Hematology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Blood Advances?
The latest impact factor listed by LetPub is 7.6; CiteScore 11.8, h-index 133.
How long does peer review take at Blood Advances?
Based on the dates recorded on 148 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 107 days (interquartile range 70–151 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Blood Advances based?
Of the 87 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (64), Australia (7) and United Kingdom (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Blood Advances?
According to LetPub and DOAJ records, Blood Advances is indexed in SCIE, Scopus and DOAJ.
Is Blood Advances open access, and what is the APC?
Blood Advances is a fully open-access journal. APC about USD 4,000.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .